Skip to search formSkip to main contentSkip to account menu

BCX 34

Known as: BCX-34 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

peldesine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2000
Review
2000
Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis.
Purine nucleoside phosphorylase (PNP) is one of the enzymes comprising the purine salvage pathway , and is responsible for the… 
Review
2000
Review
2000
An oncologist's approach to therapy for cutaneous T-cell lymphoma.
Cutaneous T-cell lymphoma (CTCL) includes a heterogeneous group of diseases manifested in many cases by a prolonged clinical… 
1999
1999
Preformulation studies for the development of a parenteral liquid formulation of the immunomodulator, peldesine.
Peldesine (BCX-34) is a potent inhibitor of the enzyme purine nucleoside phosphorylase (PNP). The object of this study was to… 
1999
1999
DERMATOPHARMACOKINETIC OF TOPICAL BCX-34 CREAM IN HUMAN SKIN
1998
1998
Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells.
1998
1998
In vitro study of BCX-34: a new human T-lymphocyte-specific purine phosphorylase inhibitor.
1997
1997
High-performance liquid chromatographic determination of 9-(3-pyridylmethyl)-9-deazaguanine (BCX-34) in biological fluids.
1997
1997
New AIDS study suppresses T cells to stop viral growth.
A controversial new study of the experimental drug BCX-34 is underway by Biocryst Pharmaceuticals. The drug suppresses T cells… 
1997
1997
Antiproliferative mechanism of BCX-34 in normal human peripheral blood mononuclear cells (PBMCs)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)